[Effectiveness of metabolic preparations in complex treatment of elderly patients with postinfarction cardiosclerosis and circulatory insufficiency].
The paper presents the results of an examination of 129 elderly patients with CHD who had had a myocardial infarction and suffered from II-III functional class heart failure. The patients were divided into four groups. The patients in the first group were administered complex therapy (CT) only; the second group received CT plus a composition of replaceable amino acids (CRAA) sublingually and orally, the third group received CT plus a placebo and the fourth--CT plus melatonin in doses of 3 and 6 mg. The efficiency of the treatment was assessed by the dynamics of clinical manifestations and by means of echoCG and Holter ECG-monitoring; parameters of lipid peroxidation and antioxidative protectability in erythrocytes were measured. The comparison of the results suggests that addition of CRAA and melatonin in a dose of 6 mg to CT is more effective than CT only. This was proved by the more pronounced positive dynamics of clinical symptoms, the improval of the myocardial contractility and normolizing influence on the balance in the oxidant/antioxidant system.
Lisitsa
G V
GV
Zaslavskaia
R M
RM
Kalinina
E V
EV
D000284:Administration, Oral; D000286:Administration, Sublingual; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000596:Amino Acids / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage*; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D004359:Drug Therapy, Combination; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008550:Melatonin / Q000008:administration & dosage; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D012598:Sclerosis / Q000188:drug therapy; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
D000319:Adrenergic beta-Antagonists; D000596:Amino Acids; D000975:Antioxidants; D014665:Vasodilator Agents; D008550:Melatonin